In the wake of the negative HPS2-THRIVE study announced last month, Merck said today that it was beginning to suspend the worldwide availability of Tredaptive, its combination of extended-release niacin and laropiprant.
One-stop source for cardiology news and links
In the wake of the negative HPS2-THRIVE study announced last month, Merck said today that it was beginning to suspend the worldwide availability of Tredaptive, its combination of extended-release niacin and laropiprant.
Developed By: SKSDEV
"I’d rather read Larry Husten on clinical trials than the constipated editorials in peer review journals." --Saurabh Jha (The Health Care Blog)
Copyright © 2023 · Prose on Genesis Framework · WordPress · Log in
Speak Your Mind